A bounded review of one sponsor-funded randomized, placebo- and active-controlled Phase 2 dose-finding trial in weight management.1
Bottom line from this bounded source set
The reviewed Phase 2 trial reported greater mean weight reduction with cagrilintide than placebo across the tested groups. A single 26-week dose-finding trial does not establish long-term outcomes or uncommon harms.1
Reviewed study record
Phase 2 weight-management trial
Design
A multicenter, randomized, double-blind, placebo-controlled and active-controlled dose-finding trial assessed body-weight change over 26 weeks.1
Population
The trial randomized 906 adults without diabetes across 57 sites in ten countries: 706 to cagrilintide groups, 99 to liraglutide, and 101 to placebo. Participants had obesity, or overweight with hypertension or dyslipidemia.1
Outcomes reported
Reported mean body-weight reduction ranged from 6.0% to 10.8% across cagrilintide groups and was 3.0% with placebo. Gastrointestinal events occurred more often across cagrilintide groups than with placebo.1
Limitations
This was a sponsor-funded, 26-week Phase 2 dose-finding study in adults without diabetes, with a short off-treatment follow-up and no long-term clinical-outcomes assessment.1
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/s0140-6736(21)01751-7. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗